High-Dose Recombinant Canarypox Vaccine Expressing HIV-1 Protein, in Seronegative Human Subjects

BackgroundIn clinical trials, canarypox ALVAC–human immunodeficiency virus (HIV) vaccines have been shown to elicit human HIV–specific cytotoxic T lymphocyte (CTL) responses in some but not all healthy uninfected adults MethodsA clinical trial was conducted to examine whether the vaccine vCP1452 wou...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The Journal of infectious diseases 2005-10, Vol.192 (7), p.1249-1259
Hauptverfasser:	Goepfert, Paul A., Horton, Helen, McElrath, M. Juliana, Gurunathan, Sanjay, Ferrari, Guido, Tomaras, Georgia D., Montefiori, David C., Allen, Mary, Chiu, Ya-Lin, Spearman, Paul, Fuchs, Jonathan D., Koblin, Beryl A., Blattner, William A., Frey, Sharon, Keefer, Michael C., Baden, Lindsey R., Corey, Lawrence
Format:	Artikel
Sprache:	eng
Schlagworte:	AIDS vaccines AIDS Vaccines - administration & dosage AIDS Vaccines - genetics AIDS Vaccines - immunology Antibodies Applied microbiology Biological and medical sciences Dosage Double-Blind Method Female Fundamental and applied biological sciences. Psychology HIV HIV 1 HIV Antibodies - blood HIV Seronegativity - immunology HIV-1 - immunology HIV/AIDS Humans Infectious diseases Interferon-gamma - metabolism Male Medical sciences Microbiology Miscellaneous Placebos Recombinant Proteins - immunology Recombinant Proteins - metabolism Response rates T lymphocytes T-Lymphocytes, Cytotoxic - immunology Treatment Outcome Vaccination Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects) Vaccines, Synthetic - administration & dosage Vaccines, Synthetic - immunology Viral Proteins - genetics Viral Proteins - immunology Viral Proteins - metabolism Virology Viruses
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!